FIGURE 1

Combination dose matrix of TNO155 and nazartinib evaluating their anti-proliferative effects against PC-14 and NCI-H1975 cells.




FIGURE 2

Immunoblot of indicated proteins with lysates from PC-14 cells that were treated with nazartinib (0.1 or 0.3 μM), 3 μM TNO155, or the combination of nazartinib and TNO155 for 4 h or 24 h.




FIGURE 3

Percentage change in tumor volumes of EGFR mutant NSCLC patient-derived xenografts in nude mice over time following treatment with vehicle, osimertinib (10 mg/kg of body weight (mpk), daily), TNO155 (10 mpk, twice daily), or the combination of osimertinib and TNO155.

